Overall survival following heterogeneous FDG-guided dose-escalation for locally advanced NSCLC in the international phase III NARLAL2 trial.

Metadata

Item Type:	Article
Authors/Creators:	Schytte, T. Kristiansen, C. Khalil, A. Hansen, O. Land, L.H. Brink, C. Nielsen, T. Nielsen, M. Hansen, T.S. Poehl, M. Persson, G. Haakensen, V. Halvorsen, T.O. Sundby, F. Schmidt, H. Hoffmann, L. Appelt, A.L. https://orcid.org/0000-0003-2792-9218 Møller, D.S. Lutz, C. Knap, M.
Copyright, Publisher and Additional Information:	This is an author produced version of a conference paper accepted for publication in Journal of Clinical Oncology. Uploaded in accordance with the publisher's self-archiving policy.
Dates:	Published (online): 5 June 2024 Published: 10 June 2024
Institution:	The University of Leeds
Academic Units:	The University of Leeds > Faculty of Medicine and Health (Leeds) > School of Medicine (Leeds) > Leeds Institute of Medical Research (LIMR) > Division of Oncology
Depositing User:	Symplectic Publications
Date Deposited:	28 Jun 2024 13:30
Last Modified:	05 Jun 2025 00:30
Status:	Published
Publisher:	American Society of Clinical Oncology
Identification Number:	10.1200/jco.2024.42.17_suppl.lba8069
Open Archives Initiative ID (OAI ID):	oai:eprints.whiterose.ac.uk:213858

CORE (COnnecting REpositories)